© 2026 SEISMIC TX. All Rights Reserved. | Privacy Policy
Watertown, Mass., January 6, 2026 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced an update to its presentation scheduled at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Jo Viney, Ph.D., Founder, President and Chief Executive Officer, will now present a company overview on Monday, January 12, 2026, at 1:30 p.m. PT.
Members of the Seismic management team will also be available for one-on-one meetings.
About Seismic Therapeutic
Seismic Therapeutic™ is a clinical-stage biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact:
Kathryn Morris
The Yates Network
kathryn@theyatesnetwork.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
seismictx@gilmartinir.com
Preclinical results demonstrate that immunoglobin G (IgG) cleaving enzymes can address the primary pathogenic mechanism in myasthenia gravis, an autoimmune disorder, by degrading immunoglobulins in circulation and in immune complexes, thereby eliminating complement deposition
Findings also reveal the role of immunoglobin M (IgM) in activation of the complement system in myasthenia gravis disease pathology
Publication in Proceedings of the National Academy of Sciences results from a collaboration between Seismic and academic investigators
Watertown, Mass., October 21, 2025 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the publication of data on the activity of its engineered pan-immunoglobin enzymes in myasthenia gravis, an autoantibody-driven disease in the Proceedings of the National Academy of Sciences (PNAS). The article is titled “Therapeutic IgG and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.”
The research is part of an ongoing multi-year collaboration between Seismic and Yale University and was led by Kevin O’Connor, Ph.D., Professor of Neurology and Immunobiology at Yale School of Medicine and an internationally recognized expert in B cell-mediated autoimmune diseases.
The published experiments investigated the cleavage of anti-acetylcholine receptor (AChR) autoantibodies and three pathogenic mechanisms that contribute to myasthenia gravis, including activation of the complement system—a primary driver of structural damage at the neuromuscular junction. Results showed how Seismic’s engineered pan-immunoglobin G (IgG) enzymes cleaved pathogenic AChR autoantibodies in both circulation and as part of immune complexes, effectively inhibiting complement activation.
The study also demonstrated that AChR-IgM is also a significant driver of complement deposition in myasthenia gravis, acting alone or synergistically with IgG in distinct patient subsets. These pathogenic effects were fully blocked by an IgM-specific protease engineered by Seismic.
“These data demonstrate the power of our platform to engineer proteases that can uniquely target mechanisms underlying disease pathology,” said John Sundy, Chief Medical Officer & Head of Research and Development at Seismic Therapeutic. “We are proud to partner with Dr. O’Connor and his team at Yale to advance the scientific understanding of myasthenia gravis, and how our Ig-targeted enzymes may enable a more comprehensive approach to treating the pathogenic mechanisms that drive autoantibody-mediated diseases.”
The publication in PNAS can be accessed via this link.
About Seismic Therapeutic
Seismic Therapeutic™ is a clinical-stage biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network LLC
kathryn@theyatesnetwork.com
Investor Contact
Ami Bavishi or Nick Colangelo, Gilmartin Group LLC
seismictx@gilmartinir.com
S-1117 offers a new therapeutic opportunity in autoantibody-mediated diseases such as myasthenia gravis and ITP
Company plans to develop S-1117 for chronic and acute treatment of IgG autoantibody-driven diseases and expects to initiate first-in-human Phase 1 clinical trial in 1H 2025
Watertown, Mass., December 9, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the 66th American Society of Hematology (ASH) Annual Meeting taking place on December 7-10 in San Diego, CA. Preclinical data for S-1117 demonstrated superior efficacy in prophylactic and therapeutic murine models of acute immune thrombocytopenia (ITP) compared to a benchmark neonatal Fc receptor (FcRN) inhibitor therapy. ITP is an autoimmune disease that causes the body to attack its own platelets, resulting in low platelet count and bleeding.
S-1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies. Within a single molecule, S-1117 addresses multiple, clinically validated, orthogonal pathogenic mechanisms, which may result in superior clinical outcome in autoantibody-mediated disorders, such as ITP and myasthenia gravis. Seismic plans to develop S-1117 for both chronic and acute treatment of IgG autoantibody-driven diseases and expects to initiate a Phase 1 clinical trial of S-1117 in healthy volunteers in the first half of 2025.
“Enzymatic IgG degradation by S-1117 offers a new therapeutic approach to address autoantibody-mediated diseases. The new preclinical ITP mouse model data further validates the speed, depth and magnitude of the IgG reduction we can achieve in vivo with S-1117, as well as its superior activity in this setting compared to a benchmark FcRN inhibitor,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “These results, combined with the previously disclosed profile of S‑1117, continue to highlight its potential as a fast acting, treat-to-target drug for chronic and acute settings.”
The S-1117 preclinical data at ASH 2024 builds upon the recently-presented results from in vitro and in vivo studies, which showed that S-1117 achieved deep, rapid and sustained reduction of all IgG subclasses and was able to directly cleave circulating and immune complexed IgG, as well as the IgG B cell receptor expressed on memory B cells. S-1117 also has the potential for a convenient, small volume, subcutaneous, self-administered treatment regimen administered every 4-6 weeks.
In the efficacy studies in animal models of ITP, acute ITP was induced in mice by rabbit anti-mouse platelet serum (or RAMS) injections, and S-1117 was administered before or after RAMS injections in the prophylactic model or therapeutic model, respectively. The new efficacy data presented at ASH 2024 includes the following highlights:
The poster for the data presented at ASH 2024 is available here on Seismic’s website.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Novel dual-cell bidirectional antibody engages two independent inhibitory receptors on multiple cell types in a single molecule
S-4321 is a low affinity PD-1 agonist with selective and functional FcγRIIb binding, without cell depleting activity
New preclinical data support differentiated profile, demonstrate induction of regulatory T cells and activity in a murine model of graft versus host disease
Company expects to initiate Phase 1 clinical trial of S-4321 in 1H 2025
Watertown, Mass., November 18, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new data for S-4321, its next generation PD‑1: FcγRIIb‑selective bifunctional agonist antibody for the treatment of autoimmune disease, at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, taking place in Washington, DC, on November 14-19, 2024. Based on the promising preclinical results, Seismic plans to initiate a Phase 1 clinical trial of S-4321 in healthy volunteers in the first half of 2025.
The presentation at ACR Convergence 2024 shows preclinical results supporting the mechanism of action of S-4321 and progress towards the clinic. S-4321 was designed using the Company’s IMPACT platform to agonize the inhibitory PD-1 receptor on T cells in the similar manner as its natural ligand, and to selectively bind and agonize the inhibitory FcγRIIb receptor on B cells/antigen presenting cells (APCs) without causing PD-1 expressing cell depletion.
Highlights of the poster presentation entitled, “S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease,” include:
“We deliberately designed S-4321 as a novel bifunctional antibody with optimal agonism of both PD-1 and FcγRIIb inhibitory receptors in a single molecule,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “We believe the distinct profile of S-4321 will translate into superior drug activity and clinical benefit in a number of prevalent autoimmune diseases. We look forward to entering the clinic in healthy volunteers in the first half of 2025, where we will assess biomarkers of PD-1 agonist activity that are enabled by S‑4321’s differentiated mechanism.”
The poster for the data presented at ACR is available here on Seismic’s website.
At ACR Convergence 2024, Seismic also presented a poster on its second program preparing to initiate clinical development, S-1117, an engineered pan-IgG protease suitable for chronic administration, for the treatment of autoantibody-mediated diseases. The poster for the data presented at ACR is available here on Seismic’s website.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Watertown, Mass., November 7, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that company management will participate in the following investor conferences:
Guggenheim’s Inaugural Healthcare Innovation Conference
Date: Wednesday, November 13, 2024
Location: Boston, MA
Format: Jo Viney, Ph.D., Founder, President and CEO, will be a speaker at the panel presentation titled, “Immunology & Inflammation: Cutting-Edge Technologies Driving the Next Wave of Biotech Breakthroughs”
Stifel Healthcare Conference 2024
Date: Tuesday, November 19, 2024
Location: New York, NY
Format: Company presentation and 1×1 meetings
Jefferies London Healthcare Conference
Date: Tuesday, November 19 – Thursday, November 21, 2024
Location: London, England, UK
Format: 1×1 meetings
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Location: New York, NY
Format: Company presentation and 1×1 meetings
Wells Fargo Virtual Private Biotech Symposium
Date: Thursday, December 12, 2024
Location: Virtual
Format: 1×1 meetings
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
IMPACT platform deployed to design Company’s lead drug candidates, S-1117 and S-4321, which are on track to enter the clinic in 1H 2025
New data indicate platform’s potential to create additional novel biologics beyond pan-IgG proteases and agonist antibodies
Watertown, Mass., November 6, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of data supporting the broad ability of its IMPACT platform to create novel biologic medicines. The data show how the IMPACT platform was leveraged to design S-1117, an engineered pan-IgG protease suitable for chronic administration and one of the Company’s lead programs, and support its generalizability to create additional biologic modalities beyond pan-IgG proteases. These data on the enhanced capabilities of the IMPACT platform are being highlighted in an invited talk today at the 16th PEGS Europe Protein and Antibody Engineering Summit (PEGS Europe 2024) in Barcelona, Spain.
Seismic’s IMPACT platform integrates machine learning with structural biology, protein engineering, and translational immunology for parallel, multi-property optimization of novel biologic therapies. The Company has built proprietary machine learning algorithms to simultaneously improve developability, modulate function, and minimize immunogenicity to enable the accelerated creation of biotherapeutics.
“We’re very excited to present new data on selected enhancements to Seismic’s IMPACT platform that demonstrate the benefits of integrating machine learning into the drug creation process to rapidly design and optimize novel drug-like protein therapeutics,” said Nathan Higginson-Scott, PhD, Chief Technology Officer at Seismic Therapeutic. “A key component of our approach is the ability to predict and remove both T and B cell epitopes beyond current state-of-the-art techniques, while maintaining other key attributes required to design biologic drugs.”
The oral presentation at PEGS Europe 2024 by Ryan Peckner, PhD, Director and Head of Machine Learning at Seismic Therapeutic, includes the following highlights:
“Application of our IMPACT platform to new protein therapeutics for diseases of the immune system has enabled us to make rapid inroads into the design and development of our lead drug candidates – S-1117 , as well as S-4321, a dual-cell bidirectional PD-1 antibody agonist – that are on track to enter the clinic in the first half of 2025,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “These data show how we are strengthening our IMPACT platform to serve as our product engine, creating a range of biologic therapies designed to address diseases more effectively by optimizing for function, minimizing immunogenicity, and enhancing drug-like properties of biologic therapies.”
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are created and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Watertown, Mass., November 5, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company’s participation in four upcoming scientific and medical conferences, presenting on Seismic’s emerging pipeline of novel therapeutics to treat autoimmune and inflammatory diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.
Details of Seismic’s presentations and poster sessions are as follows:
IMPACT platform presentation:
November 5-7: PEGS Europe Protein & Antibody Engineering Summit, Barcelona, Spain
Presentation Title: Machine learning for multi-objective optimization of bacterial proteases that degrade pathogenic immunoglobulins
Session: Machine Learning Approaches for Protein Engineering: Part 1
Date: Wednesday, November 6
Time: 6:45 p.m. CET
Presenter: Ryan Peckner, PhD, Director, Head of Machine Learning
Pipeline program presentations:
November 14-19: American College of Rheumatology (ACR) Convergence, Washington, DC
Poster Title: Preclinical polypharmacology of S-1117, a novel engineered Fc-fused IgG degrading enzyme, for chronic treatment of autoantibody-mediated diseases
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date: Saturday, November 16
Time: 10:30 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine
Poster Title: S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease
Session: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date: Monday, November 18
Time: 10:30 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine
December 7-10: American Society of Hematology (ASH) Annual Meeting, San Diego, CA
Poster Title: Preclinical polypharmacology of S-1117, a novel engineered Fc-fused IgG degrading enzyme, for chronic treatment of autoantibody-mediated diseases
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Publication Number: 2562
Date: Sunday, December 8
Time: 6:00 p.m. PT
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine
December 15-19 – Antibody Engineering and Therapeutics Conference, San Diego, CA
Presentation Title: Dual Cell Bidirectional Antibodies for Treating Autoimmunity
Session: Main Conference
Date: Wednesday, December 18
Time: 11:00 a.m. PT
Presenter: Jyothsna Visweswaraiah, PhD, Director, Head of Biotherapeutics
In addition to the presentation, Dr. Visweswaraiah will serve as co-chair for the “Forward and reverse translation medicine” session on Monday, December 16 at 2:25 p.m. PT.
Poster Title: Engineering and development of an IgG degrading enzyme therapeutic using the IMPACT platform
Presenter: Allison Colthart, PhD, Principal Scientist Drug Creation
Poster Title: Discovery and Characterization an FcgRIIb-Selective PD-1 Agonist for the Treatment of Autoimmunity
Presenter: Colin Lipper, PhD, Senior Scientist, Drug Creation
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Novel engineered Fc-fused pan-IgG protease demonstrates deep, rapid and sustained reduction of IgG levels and ability to address multiple pathogenic mechanisms as a single drug molecule
Preclinical data supports potential for S-1117’s multi-mechanistic action to address unmet need in myasthenia gravis
Company expects to initiate first-in-human Phase 1 clinical trial of S-1117 in 1H 2025
Watertown, Mass., October 15, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2024 annual meeting in Savannah, Georgia.
S-1117 is a novel engineered Fc-fused pan-IgG protease targeting IgG autoantibodies that play a key role in the pathogenesis of a range of chronic and acute autoantibody mediated diseases, including myasthenia gravis (MG), a chronic neuromuscular autoimmune disorder. Seismic plans to initiate a Phase 1 clinical trial of S-1117 in healthy volunteers in the first half of 2025.
“S-1117 has shown the unique ability to target multiple orthogonal pathogenic mechanisms within a single molecule, and we believe this multi-mechanistic approach has the potential to drive deeper responses and offer improved clinical outcomes for MG patients, as well as for patients with other autoantibody-mediated diseases,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic. “Despite recent treatment advancements, there remains a significant opportunity to address the large proportion of MG patients who do not achieve remission or low disease activity with currently approved therapies. We believe S‑1117 can offer advantages over existing treatment options and look forward to advancing S‑1117 into first-in-human Phase 1 clinical studies in the first half of next year.”
The S-1117 preclinical data presented at AANEM showed deep, rapid and sustained reduction of all IgG subclasses. S-1117 also demonstrated the ability to directly cleave circulating and immune complexed IgG, as well as the IgG B cell receptor expressed on memory B cells. Moreover, current S-1117 PK/PD modeling indicates the potential for a convenient small volume, subcutaneous, self-administered treatment regimen administered every 4-6 weeks.
Highlights of the Presentation
In vitro, S-1117 was shown to cleave soluble forms of IgG from healthy volunteers and MG patients. The results support additional key attributes of S-1117:
In vivo studies performed with S-1117 in rabbit and mouse models showed rapid, deep and sustained IgG reduction and demonstrated cleavage of the B cell receptor within hours after both intravenous and subcutaneous administration.
Projections of human PK and PD through quantitative systems pharmacology (QSP) modeling for S-1117 indicate that infrequent chronic low doses can achieve titratable IgG reductions of 90% or greater. PK/PD modeling further supports the potential for a subcutaneous, self-administered treatment regimen to achieve therapeutic levels of IgG reduction at doses as low as <1mg/kg of drug administered monthly. In addition, given the rapid onset of action, S-1117 is predicted to be applied to acute conditions, such as MG crisis.
The poster for the data presented at AANEM is available here on Seismic’s website.
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
Watertown, Mass., September 30, 2024 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company’s participation in three upcoming scientific and medical conferences, presenting on Seismic’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.
Details of Seismic’s presentations and poster sessions are as follows:
October 3-4: Biologics US, San Diego, CA
Presentation Title: Structure empowered IMPACT platform in the discovery & development of Immunoglobulin Sculpting (IgSc) enzyme & Dual-cell Bidirectional (DcB) antibody drugs for immunological diseases
Session: Track 1: Computational Tools, AI/ML-Guided Engineering
Date: Friday, October 4
Time: 2:15 p.m. PT
Presenter: Yi Xing, PhD, Senior Director, Head of Structural Biology
October 15-18: Myasthenia Gravis Foundation of America Scientific Session at American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, Savannah, GA
Presentation Title: Preclinical pharmacology of S-1117, a novel engineered Fc-fused IgG cleaving enzyme, for chronic treatment of autoantibody-mediated diseases including Myasthenia Gravis
Session: Therapeutics
Date: Tuesday, October 15
Time: 10:10 a.m. ET
Presenter: Julia Manasson, MD, Medical Director, Clinical & Translational Medicine
October 15-18: CHI Immunogenicity & Bioassay Summit, Washington, DC
Presentation Title: Machine learning for deimmunization and multi-objective optimization of biologics
Session: Immunogenicity Prediction & Control – Deimmunization, Developability, and Machine Learning
Date: Friday, October 18
Time: 3:35 p.m. ET
Presenter: Ryan Peckner, PhD, Director, Head of Machine Learning
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com
This links to an external website.